Credit: Photographer: Adam Glanzman/Bloomberg via Getty Images
Biogen sees more than 330 departures from MA-based sites since last summer
The decline and fall of Biogen’s controversial Alzheimer’s drug Aduhelm — from snap approval to payer coverage denials and now a
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
